Is Donepezil (Aricept) used for treating anorexia (loss of appetite)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Donepezil and Anorexia

  • Donepezil, also known as Aricept, is not typically used to treat anorexia (loss of appetite) 1, 2, 3, 4, 5.
  • In fact, anorexia is listed as a potential adverse effect of donepezil in several studies 1, 2, 3, 4.
  • The primary use of donepezil is for the treatment of mild to moderate Alzheimer's disease, where it has been shown to improve cognitive function and global clinical state 1, 2, 3, 5.

Adverse Effects of Donepezil

  • Common adverse effects of donepezil include nausea, diarrhea, headache, insomnia, dizziness, rhinitis, vomiting, asthenia/fatigue, and anorexia 1, 2, 3.
  • These adverse effects are often most pronounced during dose initiation or adjustment 3.
  • Donepezil has been found to have a favorable safety profile, with no significant effects on laboratory evaluations and no association with hepatotoxicity 2, 3.

Alternative Administration Methods

  • Researchers have explored alternative administration methods for donepezil, such as lyotropic liquid crystalline mesophases, to reduce gastric side effects like anorexia 4.
  • These alternative methods aim to provide a more controlled release of the drug, potentially reducing adverse effects and improving patient outcomes 4.

References

Research

Donepezil for mild and moderate Alzheimer's disease.

The Cochrane database of systematic reviews, 2000

Research

Donepezil: tolerability and safety in Alzheimer's disease.

International journal of clinical practice, 2002

Research

Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.